CRY1 and ovarian carcinoma: As CRY1 had been previously shown to undergo aberrant DNA methylation events in various solid human malignancies including breast and ovarian cancers [3], [7], [22], we examined whether epigenetic silencing could also explain the observed CRY1 mRNA expression differences in CLL subgroups.